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Mammalian aging results from a replicative decline in the function of somatic stem cells and other 
self-renewing cells. Recent studies (Monzen et al., 2008; Nishino et al., 2008; Sanna et al., 2008; 
Weedon et al., 2008) link a chromatin-associated protein, HMGA2, to development, height, and 
mouse stem cell aging during late fetal development and young adulthood.Aging: A Disease of Declining Replicative Function
It appears that we get old in part because our somatic stem cells 
get old. In several types of tissues, the replicative function of 
somatic stem cells declines with age, and this in turn is associ-
ated with many common phenotypes characteristic of aging. This 
decline in replicative function clearly has multiple causes, includ-
ing both intrinsic changes within self-renewing cells and extrinsic 
changes to the supporting milieu (Sharpless and DePinho, 2007). 
Some aspects of stem cell aging, however, seem to result from 
the activation of important anticancer mechanisms. Continuously 
proliferating, self-renewing cells make mistakes during DNA repli-
cation and accumulate DNA damage with age (Rossi et al., 2007). 
Therefore, the activation of tumor suppressor mechanisms in 
aged, damaged cells is desirable, as this prevents their malignant 
transformation. Unfortunately, these mechanisms also contrib-
ute to the functional decline of self-renewing compartments with 
aging, and thus we grow old.
The evidence for this model of tumor suppressor-driven aging 
is perhaps strongest for the p16INK4a tumor suppressor gene, 
encoded by the INK4/ARF (or CDKN2a/b) locus. This protein is a 
potent effector of cell-cycle arrest and plays a significant role in the 
in vitro senescence of numerous cell types (Gil and Peters, 2006). 
Expression of p16INK4a increases sharply with age in the major-
ity of mammalian tissues (Sharpless and DePinho, 2007). In stem 
cell populations in the brain and bone marrow, p16INK4a expression 
mediates a heritable decline in replicative function due to either 
a deficiency in BMI-1 (a repressor of INK4a/ARF expression) or 
noxious insults such as ionizing radiation. Mice lacking p16INK4a 
maintain the replicative function of neural stem cells, hematopoi-
etic stem cells, and pancreatic β cells as they age (Sharpless and 
DePinho, 2007). Most recently, loss of p16INK4a has been shown to 
attenuate many complex age-related phenotypes in a progeroid 
mouse strain that ages prematurely (Baker et al., 2008). Therefore, 
p16INK4a expression not only correlates with aging in these tissues 
but also in part causes aspects of their aging. Support for this 
model in humans has come from recent candidate and genome-
wide association studies independently linking single-nucleotide 
polymorphisms (SNPs) near the INK4/ARF locus to several human 
age-associated conditions, including type 2 diabetes, atheroscle-
rosis, and the geriatric wasting disorder termed frailty syndrome 
(Sharpless and DePinho, 2007).The INK4/ARF Locus: Handle with Care
Several different labs have generated over 15 different mouse 
strains harboring disruptions of the murine Ink4/Arf locus, 
which encodes p16INK4a and two other tumor suppressor genes, 
p15INK4b and Arf (Gil and Peters, 2006). A consistent finding is 
that these animals are surprisingly normal through young adult-
hood. Mice lacking p16INK4a, Arf, and p15INK4b, either alone or in 
combination, are viable, fertile, and not easily distinguished 
from their wild-type littermates, until they develop tumors. This 
observation suggests that the INK4/ARF locus, and in par-
ticular the p16INK4a gene, is dispensable in the development of 
most tissues but plays a life-long role in tumor suppression. 
This potent tumor suppressor locus appears to be activated at 
an early stage of neoplastic progression by common features 
present in would-be cancer cells. However, as cells activate 
INK4/ARF expression, they also lose their capacity for further 
proliferation, perhaps permanently. Therefore, this beneficial 
anticancer mechanism also contributes to the attrition of func-
tional stem cells with aging.
If the major function of p16INK4a, and perhaps other mem-
bers of the INK4/ARF locus, is to quell the hyperproliferation of 
once-normal cells that have stochastically “gone bad,” one can 
clearly see that the expression of such a locus must be care-
fully controlled. In particular, regulation of INK4/ARF expres-
sion during embryonic development would be crucial. Many 
developing tissues demonstrate incredible rates of prolifera-
tion that are coupled with cell migration and rapid changes 
in the extracellular milieu. How would a cell know that these 
developmentally programmed events, which share many traits 
with aberrant malignant growth, are normal and not a cause 
for INK4/ARF activation? Evidence suggests that this problem 
is addressed in adult mammals by potent mechanisms that 
silence the INK4/ARF locus until it is derepressed by an age-
induced activation of p16INK4a. But how the INK4a/ARF locus 
is regulated during embryogenesis and early postnatal life is 
unclear.
HMGA2 Regulates INK4a/ARF in Stem Cells
Against this backdrop, a recent study in Cell by Nishino et al. 
(2008) identifies the chromatin-associated protein HMGA2 as a 
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expression in mice. The authors performed an unbiased screen 
for transcripts that are highly expressed in fetal stem cells but 
decrease in expression postnatally and with aging. They identified 
one transcript, Hmga2, that satisfies these criteria and exhibits 
decreased expression in hematopoietic stem cells as well as in 
two types of neural stem cells.
There are four high mobility group A (HMGA) family proteins: 
three isoforms of HMGA1 and HMGA2. These chromatin-asso-
ciated proteins appear to lack intrinsic transcriptional activity 
but instead bind to AT-rich DNA sequences and potentiate the 
effects of transcription factors by altering local chromatin struc-
ture (Fusco and Fedele, 2007). For example, a recent Nature Cell 
Biology paper by Monzen et al. (2008) reports that knockdown 
of HMGA2 blocks cardiomyocyte differentiation of an embryo-
nal carcinoma cell line and completely abrogates in vivo car-
diogenesis in embryos of the frog Xenopus laevis. The authors 
demonstrate that HMGA2 cooperates with Smad transcription 
factors to induce expression of Nkx2.5, which encodes an impor-
tant early transcription factor for cardiac development. This is 
accomplished through HMGA2 binding to a conserved AT-rich 
region in the Nkx2.5 promoter. HMGA2 has also been strongly 
associated with neoplasia, inducing diverse oncogenic effects on 
the cell cycle, apoptosis, and differentiation (Fusco and Fedele, 
2007). Mice overexpressing Hmga2 develop lymphoid, lipoid, and 
pituitary tumors. In humans, genetic amplifications or transloca-
tions of HMGA2 that augment its expression are associated with 
a variety of common benign mesenchymal tumors as well as rare 
aggressive cancers (Fusco and Fedele, 2007).
Nishino et al. (2008) show that HMGA2 plays an age-associ-
ated role in the self-renewal of mouse neural stem cells (NSCs). 
Although HMGA2 does not appear to be required for the gen-
eration of NSCs during fetal development, NSCs from Hmga2-
deficient mice have defects in proliferation and self-renewal. 
Differentiating neural progenitors from these mice do not exhibit 
proliferative defects, suggesting that Hmga2 loss does not 
lead to a global decrease in cellular replication but specifically 
affects stem cell self-renewal. Importantly, in accordance with the 
observed expression pattern of Hmga2, the negative effects of 
HMGA2 on proliferation are most pronounced in NSCs derived 
from late embryos or very young mice and decline with aging. In 
fact, NSC number and function are similar in old Hmga2-deficient 
mice and wild-type littermates, indicating that physiological aging 
of normal mice reduces NSC function to a level comparable to 
that established in Hmga2-deficient mice during development. 
The alterations in stem cell function in Hmga2-deficient young 
mice are associated with neuroanatomical changes, including 
decreased cellular proliferation in the subventricular zone (where 
NSCs reside) and fewer neurons in the central and peripheral ner-
vous systems.
When the authors analyzed p16INK4a and Arf expression in 
mouse NSCs lacking Hmga2, they found that stem cells from 
late-stage embryos and young mice markedly overexpress 
both genes of the Ink4a/Arf locus. Interestingly, the degree of 
Ink4a/Arf overexpression inversely correlates with declining 
Hmga2 expression from late fetal life to old age, suggesting 
a direct link between this locus and HMGA2. Indeed, the self-
renewal defects of Hmga2-deficient NSCs could be partially 
rescued by the loss of p16INK4a or Arf expression. Consistent 1014 Cell 135, December 12, 2008 ©2008 Elsevier Inc.with the proliferative defects seen in NSCs, the alterations in 
Ink4a/Arf expression are strongly correlated with age. Overex-
pression of p16INK4a and Arf is most pronounced in late-stage 
embryos and young-adult mice but decreases with age. As 
expression of Ink4a/Arf normally sharply increases in NSCs 
with age, wild-type mice appear to eventually “catch up” with 
Hmga2-deficient mice regarding Ink4a/Arf expression. The 
expression of p16INK4a and Arf is roughly comparable in NSCs 
from old (?2 years) mutant and wild-type mice, indicating that 
the effects of HMGA2 are most pronounced from late fetal 
development to young adulthood. Because no HMGA2 binding 
could be detected at the Ink4a/Arf locus, Nishino et al. sug-
gest that HMGA2 may control expression from this locus by 
repressing the expression of JunB, an activator of Ink4a/Arf 
expression in stem cells.
Figure 1. HMGA2 and let-7 in Mammalian Development
MicroRNAs (miRNAs) are generated as long primary transcripts (pri-miRNAs) 
that are processed by the Drosha/DGC8 complex into pre-miRNAs. Further 
processing by the endoribonuclease Dicer produces the 22 nucleotide mature 
miRNAs. Production of the let-7 miRNA during development is regulated by 
the RNA binding protein Lin-28. Mature let-7 targets multiple genes, including 
HMGA2. This architectural transcription factor represses INK4a/ARF expres-
sion, possibly through the repression of JunB.
But how is Hmga2 expression regulated in NSCs? Recent work 
has defined a posttranscriptional mechanism for the regulation of 
HMGA2 protein production by the let-7 microRNA (miRNA). The 
HMGA2 mRNA contains in its 3′ untranslated region (UTR) seven 
target sites for let-7 binding (Figure 1) (Fusco and Fedele, 2007). 
Expression of HMGA2 is high in embryonic cells and very low in 
differentiated cells, a pattern exactly inverse to that of let-7 miRNA 
family members, further suggesting a regulatory relationship. 
Nishino and colleagues analyzed the expression of the let-7 fam-
ily in aging NSCs. They show that the expression of a specific let-7 
family member, let-7b, inversely correlated with Hmga2 expres-
sion, increasing during late fetal development and adult aging. 
Satisfyingly, overexpression of let-7b in NSCs from young mice 
decreases Hmga2 expression and increases INK4a/ARF expres-
sion. Furthermore, miRNA overexpression decreases NSC self-
renewal in vitro. Together, these observations suggest an appeal-
ing model for how regulation of stem cell self-renewal by controlling 
the INK4a/ARF tumor suppressor locus can be achieved through 
modulating expression of the pleiotropic transcriptional regulator 
HMGA2 during late embryogenesis and young adulthood with let-
7b, a developmentally regulated miRNA.
The MicroRNA Connection
Accumulating evidence links miRNAs to the biology of stem cells. 
Over 600 distinct miRNAs have been discovered in the human 
genome, and each is predicted to regulate several hundred tar-
get mRNAs. The enormous regulatory potential of miRNAs may 
even surpass that of transcription factor networks. Expression of 
miRNAs is crucial for embryonic stem cell (ESC) function. Indeed, 
loss of the essential miRNA-processing enzyme Dicer causes 
a defect in ESC differentiation in vitro and the death of mouse 
embryos early in development (Stadler and Ruohola-Baker, 
2008).
The let-7 miRNA family was among the first group of miRNAs 
suggested to regulate stem cells. This evolutionarily conserved 
family of miRNAs was first described in the worm Caenorhab-
ditis elegans (Bussing et al., 2008). There are intriguing parallels 
between the effects of let-7 in C. elegans and the observations of 
Nishino et al. in the mouse. In C. elegans, let-7 is strongly induced 
in hypodermal stem cells (seam cells) coincident with their termi-
nal differentiation, and loss of let-7 function results in the contin-
ued proliferation of these cells. In mammals, let-7 expression is 
similarly induced during embryonic development and has been 
suggested to negatively regulate stem cell function in a variety 
of tissues.
Although miRNA expression is well characterized in ESCs, 
the picture is less clear in adult stem cells. This is partly due to 
the imprecise definition of most adult stem cell populations, as 
well as the inability to purify these cells to homogeneity without 
contamination from committed progenitor cells. Nonetheless, 
even though comprehensive expression analyses have not been 
performed, it is clear that specific miRNAs control the differen-
tiation state of somatic cells. Certain miRNAs have been identi-
fied that promote proliferation of epithelial progenitors, whereas 
other miRNAs promote differentiation of progenitors (Stadler and 
Ruohola-Baker, 2008). Interestingly, the let-7 family has made an 
appearance in this latter class. Progenitor cells isolated from nor-
mal mammary epithelial cells have reduced let-7 expression, and enforced let-7 expression reduces the progenitor cell population 
(Ibarra et al., 2007). Similarly, tumor-initiating cells from primary 
breast carcinoma have reduced levels of let-7 compared to the 
bulk population. Enforced let-7 expression in these cells reduces 
their proliferation and self-renewal, in part through posttranscrip-
tional regulation of HMGA2 (Yu et al., 2007a). These data present 
an overall theme of let-7 as a mediator of differentiation state and 
as an inhibitor of self-renewal.
A Lin-28-let-7-HMGA2 Axis?
Given these extensive changes in miRNA expression during 
mammalian development, how are these miRNAs regulated? 
Most miRNAs are products of RNA polymerase II and thus are 
controlled by the same transcriptional machinery as protein cod-
ing genes. In fact, the core promoters of many miRNA genes have 
been shown to be regulated by established transcription factors 
such as c-Myc, E2F, and serum response factor. Therefore, it 
came as a surprise that let-7 is not transcriptionally induced during 
mammalian development but is instead regulated posttranscrip-
tionally (Bussing et al., 2008). All miRNAs are initially generated as 
a primary transcript several thousand nucleotides in length. These 
long transcripts undergo two processing steps during maturation 
(Figure 1). The first step, catalyzed by the Drosha/DGCR8 het-
erodimer, liberates the stem-loop precursor for further processing 
by Dicer to yield the mature 22 nucleotide miRNA. Biogenesis of 
let-7 is specifically inhibited at both processing steps in embry-
onic cells (Bussing et al., 2008). It is the release of this block that 
allows mature let-7 production during differentiation, with all of 
the attendant effects on development and differentiation. Quite 
surprisingly, the processing block of let-7 miRNAs is achieved by 
interaction with the protein Lin-28 (Bussing et al., 2008; Heo et al., 
2008). The Lin-28 protein is highly expressed in ESCs and is also 
able to promote reprogramming of differentiated somatic cells 
into pluripotent stem cells (Yu et al., 2007b). It should be noted 
that Lin-28 does not appear to be a general inhibitor of miRNA 
processing but instead specifically inhibits let-7 production.
Thus, a linear pathway from Lin-28 to let-7 to HMGA2 to INK4/
ARF expression can be constructed (Figure 1). The expression 
of Lin-28 is high in ESCs, thus repressing the production of let-7. 
Given that let-7 inhibits translation of HMGA2 mRNA by the miRNA 
pathway, low levels of let-7 miRNA are predicted to allow HMGA2 
protein production in ESCs. This is precisely what is observed in 
ESCs, but could such a relationship also exist in somatic stem 
cells in adult mammals? Although the new work from Nishino 
and colleagues describes let-7 regulation of Hmga2 and Ink4a/
Arf in mouse NSCs, Lin-28 expression has not been observed 
in nonembryonic tissues. However, a functionally related protein, 
Lin-28B, has been detected in somatic tumor cells (Guo et al., 
2006), raising the possibility that Lin-28B substitutes for Lin-28 in 
NSCs. Alternatively, let-7 in NSCs could be regulated at the level 
of transcription.
Unresolved Questions
Although a pathway linking Lin-28 to INK4a/ARF expression 
through the actions of let-7 and HMGA2 is appealing (Figure 
1), it is likely to be too simplistic. HMGA2 undoubtedly regu-
lates the expression of many genes other than JunB, p16INK4a, 
and ARF. Because the effects of HMGA2 on NSC self-renewal Cell 135, December 12, 2008 ©2008 Elsevier Inc. 1015
are only partly rescued by Ink4a/Arf loss, HMGA2 must have 
Ink4a/Arf-independent effects on self-renewal. Likewise, the 
let-7 family of miRNAs has many targets other than HMGA2. 
For example, let-7 mediates the repression of RAS oncogenes 
in the self-renewal of tumor-initiating cells (Yu et al., 2007a). 
It also remains unclear whether the cancer-relevant activities 
of let-7 or HMGA2 include influencing the expression of the 
INK4a/ARF tumor suppressor locus. Therefore, elucidating 
other mediators of let-7 and HMGA2 function is essential to 
understanding their roles in somatic stem cells.
These observations also suggest a specific role for let-7 and 
HMGA2 in cancer. The let-7 miRNA appears to act as a tumor 
suppressor in part by repressing self-renewal, whereas HMGA2 
seems to have oncogenic activities that include the enhance-
ment of self-renewal. At first blush, this appears inconsistent 
with the finding that in cultured human fibroblasts, HMGA 
proteins cooperate with p16INK4a in the establishment of cellu-
lar senescence, which is a crucial tumor suppressor mecha-
nism (Narita et al., 2006). However, one should consider that 
the effects of pleiotropic regulators like the HMGA-proteins 
are likely to be different between fibroblasts and stem cells. 
Furthermore, the senescence-promoting effects of HMGA2 
in fibroblasts are far weaker than those of HMGA1. Thus, we 
do not believe these observations are in conflict. Rather, they 
illustrate that the functions of HMGA proteins are likely to be 
complex and to have cell-type and isoform-specific effects.
Like the documented effects of HMGA2 on cancer, its role in 
height determination is well established but remains mysterious. 
Two recent genome-wide association studies (GWAS) in Nature 
Genetics (Sanna et al., 2008; Weedon et al., 2008) confirm an 
association between common alleles of SNPs linked to HMGA2 
and human height. Although mechanistically understanding how 
a given SNP identified by GWAS is associated with a particular 
trait can be problematic, in this case, evidence supports a model 
in which these SNPs are associated with altered HMGA2 function. 
A spontaneous mutation of the Hmga2 gene has been previously 
shown to result in the murine pygmy phenotype, which includes 
reduced adult size (Zhou et al., 1995). Meanwhile, transgenic mice 
that overexpress a wild-type Hmga2 gene or a truncated variant 
without the 3′ UTR exhibit gigantism (Battista et al., 1999). This 
latter Hmga2 allele is of interest because the 3′ UTR truncation 
removes the let-7 binding sites, thereby abrogating the repres-
sion of Hmga2 by let-7. Furthermore, a germline chromosomal 
inversion that results in a similarly truncated human HMGA2 gene 
was identified in a boy with severe overgrowth (Ligon et al., 2005). 
The HMGA2-linked SNPs that are most strongly associated with 
height are known to lie within the 3′ UTR of HMGA2, suggesting 
that the height-influencing genetic events linked to these SNPs 
may influence let-7 binding. However, it remains to be determined 
how exactly increased HMGA2 expression would alter human 
height and whether this is related to the effects of HMGA2 on 
stem cell self-renewal and tumorigenesis in mice.
In summary, control of the age-promoting expression of 
p16INK4a and possibly other INK4/ARF-associated transcripts in 
self-renewing cells appears to be a cradle-to-grave problem for 
mammals. During late fetal development, early postnatal life, and 
young adulthood, Hmga2, under the control of the let-7 miRNA, 
seems to be a major regulator of INK4a/ARF expression. With the 1016 Cell 135, December 12, 2008 ©2008 Elsevier Inc.transition from young to old adulthood, the Polycomb group (PcG) 
chromatin remodeling complexes appear to play a principal role 
in the repression of the INK4a/ARF locus. With increasing age, 
a developmentally programmed increase in let-7 expression and 
stochastic loss of PcG-mediated silencing results in the dere-
pression of the INK4a/ARF locus and activation of p16INK4a expres-
sion in self-renewing cells. This more refined understanding of the 
regulation of somatic stem cell self-renewal can now be exploited 
in future studies to determine how healthy aging may be achieved 
without increasing the risk of malignant disease.
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